Impressive Fourth Quarter Results
Eli Lilly’s fourth quarter financials surpassed Wall Street forecasts, buoyed by the successful launch of its new weight-loss drug, Zepbound, and strong sales of its diabetes treatment, Mounjaro. The company reported adjusted earnings of $2.49 per share, significantly higher than the $2.22 analysts anticipated. Its revenue hit $9.35 billion, exceeding the expected $8.93 billion.
Zepbound’s Strong Market Entry
Zepbound, approved by U.S. regulators in early November, generated an impressive $175.8 million in sales in the fourth quarter. This robust start positions Zepbound…
Read More